New England Investors (“NEI”) and its partners combine investment banking and private equity expertise to provide strategic advice, risk management and capital advisory to clients in various industry sectors including life sciences, financial services, technology and real estate. We specialize in advising early and mid-stage businesses in North American and greater Europe, as well as restructuring established and distressed businesses.
NEI Principals have decades of experience working in global debt capital markets, as well as domestic and cross border private equity and asset-backed financing. We have significant experience in highly-structured issuances including mezzanine debt, hybrid securities, private issuances of leveraged loans and intellectual property out-licensing.
NEI Principals have previously advised on both the buy and sell side of cross-border acquisitions including several leveraged buy-outs. We have also worked with Special Purpose Acquisition Companies (SPAC’s) and their reverse mergers.
NEI Principals include former lawyers and certified public accountants with decades of experience in financial and financial reporting matters, as well as legal, tax and treasury matters. We can develop domestic or multi-jurisdictional financial strategies, cash flow forecasting and analysis, and we can assemble the pre-IPO or pre-acquisition due diligence package.
Special emphasis on financing in the life sciences industry
NEI advises North American and European biotech and pharmaceutical companies seeking to monetize their early and mid-stage pharmaceutical and biological assets.
NEI works closely with its Principals located in the People’s Republic of China (“China”) to source financing from companies domiciled in China via:
- Out-licensing to China (or in some cases, globally)
- Financial commitments via strategic joint venture and development (including pre-clinical assets)
- Distribution agreements
- Additional capital raises
Our China-based Principals:
- Are highly experienced in the pharmaceutical industry;
- Have longstanding relationships with multiple large, public and private pharmaceutical companies in China; and
- Can quickly assess the market for our clients’ assets and source potential monetization opportunities